Devyser publishes annual report for 2025
Devyser´s annual report 2025 has today been published on the company´s website.
The report is available on: https://investors.devyser.com/en/reports-presentations
The financial year covers the period from 1 January to 31 December 2025.
For more information, please contact:
Jan Wahlström, CEO
Email: [email protected]
Telephone: +46 8 562 158 50
Sabina Berlin, CFO
Email: [email protected]
Telephone: +46 8 562 158 50
About Devyser
Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.
Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.
We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US.
Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.
Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). Redeye Nordic Growth AB is the company's Certified Adviser.
Discover how we're shaping the future of lab diagnostics at www.devyser.com.